SlideShare uma empresa Scribd logo
1 de 60
بسم الله الرحمن الرحيم
Cardiovascular PharmacologyManagement of Hypertension  Dr. Mohamed saad
Cardiovascular PharmacologyManagement of hypertension  Hypertension is a major health problem with          prevalence rate of 25% among adults,         increasing to 50% among those above 60         years. Hypertension causes dangerous complications           (Target Organ Damage [TOD]) such as       myocardial infarction, heart failure, aortic       aneurysm, stroke and renal failure. These      complications occur commonly in high risk      patients as males, elderly, smokers, diabetics,       and those with high cholesterol levels.
The cause of hypertension is unknown and only less than 5% of cases are secondary to renal diseases, pheochromocytoma, hyperaldosteronism, aortic coarctation, or secondary to drugs (drug-induced hypertension) such as: ,[object Object]
Volume expanders, e.g. glucocorticoids, NSAIDs and oral contraceptives.,[object Object]
Target Blood Pressure <140/90       in low-risk group 			     <130/85       in high-risk group
Lifestyle Modification (Nonpharmacological Management of Hypertension) Beneficial in reducing high blood pressure and its complications. Reduces the dose requirement of antihypertensive drugs. Recommended in all hypertensives initially and with drug therapy.
Lifestyle modification includes :- (1). Reduced dietary intake of Na+ and fat,   increased Ca2+ and K+ intake, together with diet rich in fruits and vegetables and low-fat dairy products. (2). Weight reduction for overweight patients. (3). Regular physical exercise. (4). Stopping smoking and reducing alcohol           intake
3. Sympatholytics 2. b Blockers NE  early late Vasospasm Angiotensin II Vasodilators 4. Angiotensin Converting Enzyme Inhibitors (ACEIs) 1. Diuretics 5. Angiotensin Receptor Blockers (ARBs) 6. Calcium Channel Blockers 7. Direct Vasodilators Classification of Antihypertensive Drugs Centrally-acting  a1-blockers    BP COP TPR   = ×  
NB: Hypertensive patients can be classified into salt-sensitive and salt-resistant patients. Salt-sensitive hypertension is more common in elderly, obese, black, and patients with renal disease. These patients have impaired renal Na+ excretion leading to Na+ retention with increased Na+-Ca2+ exchange and vasoconstriction and low renin status. Hypertension in these patients gives better response to diuretics and calcium channel blockers with poor response to B-blockers and ACEIs which act mainly in high-renin status.
I. Diuretics Mechanism of Action Initially, they act by reducing plasma volume and COP, followed by vasodilation and reduction in peripheral vascular resistance. Advantages Reduce mortality, stroke and cardiovascular complications of hypertension. The least expensive antihypertensives.
Indications 1st choice in uncomplicated hypertension. Specially indicated in: 1. Systolic hypertension. 2. Hypertension in elderly, black and obese patients (salt-sensitive). 3. Hypertension complicated with heart failure. Combined with other antihypertensives to potentiate their effect: 1. Control edema of vasodilators. 2. Reduce plasma volume -> increase renin and potentiate the hypotensive action of ACEIs and b blockers, especially in black old patients.
Thiazides are the preferred diuretics for hypertension because in single daily dose they cause persistent volume depletion which is required to lower BP; whereas once daily dose of frusemide is inadequate as it causes temporary Na+ loss. Thiazides tend to retain Ca2+ -> ↓ risk of bone fracture in the elderly.
Preparations and Dosage Hydrochlorothiazide: low (12.5 mg) or lower (6.25 mg) dose combined with an ACEI or a b blocker has adequate antihypertensive effect with fewer side effects. Indapamide: a thiazide-like agent with more vasodilator effect and less side effects especially in low-dose (1.25 mg) slow-release preparations.  Frusemide: orally 2-3 times daily in hypertension with renal impairment in which case thiazide diuretics are not effective due to decreased GFR.
Side Effects-: 1. Metabolic Side Effects Hyperuricemia - hyperglycemia -hyperlipidemia. 2. Electrolyte Disturbances Hypokalemia - hyponatremia -hypomagnesemia.
These side effects can be minimized by:- a. Low-sodium and high-potassium diet. b. Using low dose of thiazide especially when combined with b blockers to avoid unfavorable additive metabolic effects. c. Combination with spironolactone in cardiac patients to avoid the dangerous effects of hypokalemia and hypomagnesemia. d. Combination with ACEIs which may neutralize these effects.
3. Impotence (common). 4. Sulfonamide hypersensitivity reactions (rare) as jaundice, pancreatitis and blood disorders.
II. B-Adrenergic Blockers Mechanism of Action-:  Initially, they decrease COP without effective drop in BP due to reflex vasospasm with early increase in TPR. Later, they decrease TPR and BP through: a. ↓ Renin release. b. ↓ NE release by central and peripheral effects. c. ↑ PG causing VD.
Advantages Decrease cardiovascular mortality & morbidity and protect against coronary heart disease.  Relatively not expensive. Indications Alternative to diuretics as 1st line treatment of uncomplicated hypertension. Used in young hypertensives where COP is high. Hypertension associated with coronary heart disease.
Preparations and Dosage The ideal antihypertensive B-blocker would be long-acting (once-daily) and b1-selective. It is best to start with low dose to lessen the initial side effects as fatigue and bradycardia due to ↓ COP. If the ordinary dose is inadequate, it is better to combine with another drug rather than to increase the dose. Atenolol 		25-100 mg Bisoprolol 2.5-10 mg. Metoprolol 	50-200 mg.
B-Blocker Combinations in Hypertension 1. b Blockers plus Diuretics Diuretics acting by Na+ loss increase renin secretion -> VC by angiotensin II thus offsetting their hypotensive effect. b Blockers inhibit renin release -> potentiate the hypotensive effect of diuretics. On the other hand, diuretics, by increasing renin level, potentiate the hypotensive effect of b blockers in low-renin hypertensives as black elderly patients. For initial therapy of hypertension, the lowest effective dose of both drugs [bisoprolol (2.5 mg) and hydrochlorothiazide (6.25 mg)] is recommended to avoid possible additive metabolic side effects such as hyperglycemia and hyperlipidemia.
2. B-Blockers plus Dihydropyridine (DHP) Ca2+ Channel Blockers DHP Ca2+ channel blockers induce vasodilator effect and reflex tachycardia, offsetting a possible vasospasm and bradycardia induced by b blockers.
Side Effects (Less with B1-selective): 1. Bronchospasm, cold extremities. 2. Metabolic: glucose intolerance, dyslipidemia. 3. Bradycardia, heart block. 4. CNS depression, sense of fatigue. 5. Impotence.
III. Calcium Channel Blockers There are two main types of voltage-dependent Ca2+ channels:- 1. L-type (Long-lasting)     with slow inactivation and high conductivity. 2. T-type (Transient)         with fast inactivation and low conductivity. Ca2+ channel blockers act on α1 subunit of L-type channel that is located in conductive tissues (SAN & AVN) cardiac myocytes and vascular smooth muscle including coronaries.
Classification, Actions, Uses and Adverse Reactions of Calcium Channel Blockers
Calcium Channel Blockers for Hypertension Mechanism of Action Peripheral VD and ↓ TPR. Diuretic action secondary to ↑ renal blood flow. ↓ Aldosterone secretion. Advantages No metabolic side effects (no changes in glucose, lipid or uric acid levels). No affection of sexual activity. May improve renal function.
Indications   :  2nd Choice after diuretics in elderly hypertensives or in isolated systolic hypertension. 2nd Choice after b blockers in hypertensives with coronary heart disease. Hypertension with peripheral vascular disease (PVD). Hypertension with renal impairment. Preparations and Dosage:  Amlodipine 5 mg once daily. Verapamil 240 mg SR once daily.
IV. Angiotensin-Converting Enzyme (ACE) Inhibitors Angiotensinogen Renin Bradykinin Angiotensin I ACE Angiotensin II  Inactive peptide AT2 Receptors ,[object Object]
Anti-proliferative.AT1 Receptors ,[object Object]
 Sympathetic (central + peripheral).
↑ Aldosterone (Na+ retention).
↑ ADH (water retention).
 Proliferation of myocytes in heart and vessel wall.AT4 Receptors? ,[object Object],↑ Fibrinogen. ↑ Plasminogen activator inhibitor I (PAI1)
Mechanism of Action of ACEIs: ACEIs have dual vasodilator action by: 1. ↓ Angiotensin II formation which mediates most of its effects through activation of AT1 receptors (inhibits vasospasm, salt & water retention & cardiac & vascular remodeling induced by angiotensin II). ↓ Activity of angiotensin II at AT2 receptors -> minimizes vasodilator effect of ACEIs (a disadvantage compared to ARBs).  ↓ Activity of angiotensin II at AT4 receptors -> ↓its prothrombotic effect mediated by ↑ fibrinogen & PAI1 (an advantage over ARBs). 2. ↑ Bradykinin through inhibition of its deactivation -> direct VD & release of potent vasodilator PGs and NO from vascular endothelium.
Therapeutic Uses of ACEIs I. Cardiovascular Uses ACE inhibitors have unique effects in preventing and treating cardiovascular diseases. They act on sequential events from risk factors to left ventricular failure.
The main cardiovascular indications of ACEIs are: Major risk factors 1. Hypertension:           ↓ BP,             } Major risk factors 				↓ LV hypertrophy 2. Ischemic heart disease: inhibits atherogenesis and thrombogenesis. 3. Myocardial infarction: Early administration during acute attacks prevents sudden death by preventing arrhythmia induced by hypokalemia and sympathetic overactivity. Decrease postinfarction remodeling caused by aldosterone and prevent heart failure. 4. Heart failure: used in all stages of heart failure. Major risk factors
II. Nephropathy (diabetic or nondiabetic) ACEIs decrease intraglomerular pressure, progressive glomerulosclerosis, and proteinuria and delay the onset of renal failure.
ADVERSE REACTIONS Related to ↑ Bradykinin Related to  ↓ Angiotensin II Related to  High DoseCaptopril (immune-base) ,[object Object]
Chronic dry cough (late).Hypotension Renal impairment Hyperkalemia (↓ aldosterone) ,[object Object]
Neutropenia
Proteinuria
Loss of taste.,[object Object]
Class I Captopril (SH) Class II Enalapril - Perindopril Ramipril - Fosinopril Class III Lisinopril Classification of ACEIs
Class I (Captopril) : Not a prodrug.  Rapid onset & short duration (t½ 4-6 h), can be given sublingually in severe hypertension ↓ Nitrate tolerance (due to its SH group). Class II (Enalapril - Perindopril - Ramipril - Fosinopril): Prodrugs (activated first in liver).  Slow onset & long duration (given once/day). Have carboxyl group not SH group with absence of immune base side effects of captopril. Fosinopril has phosphoryl group instead of carboxyl group with dual route of excretion (hepatic & renal) -> no dose adjustment in renal failure.
Classification (contin) Class III (lisinopril) : Not a prodrug. Long duration. Water soluble, not metabolized in liver and excreted unchanged by the kidney -> given in liver disease.
ACE Inhibitors in Hypertension Mechanism of Action 1. Vasodilation due to ↓ angiotensin II & ↑ vasodilator BK, PGs & NO. 2. Anti-adrenergic effect by blocking central & peripheral adrenergic activity of angiotensin II (thus ACEIs decrease BP without reflex tachycardia). 3. Inhibition of aldosterone -> Na+ loss.
Advantages 1. ↓ Cardiovascular mortality and morbidity. 2. Protect renal function especially in diabetics. 3. No metabolic side effects (no effect on glucose, lipid or uric acid). 4. May improve glucose intolerance in insulin resistance. 5. No changes in heart rate.  Indications 1. Diabetic hypertensives. 2. Hypertension with nephropathy in diabetics or nondiabetics. 3. Hypertension in HF or after myocardial infarction.
V. Angiotensin II Receptor Blockers (ARBs)(Losartan - Valsartan - Telmisartan) They block angiotensin II receptor type I (AT1) responsible for most of the damaging effects of angiotensin II (see figure p. 179). Advantages of ARBs over ACEIs 1. Antagonize AG II formed by both ACE & non-ACE pathway (e.g. chymase). 2. They are able to avoid hormonal "escape" (↑ renin & angiotensin II) which may occur during prolonged administration of ACEIs. 3. They block the hypersensitivity of AT1 receptor caused by insulin or LDL. 4. Blocking AT1 receptor directs angiotensin II to AT2 receptor which has vasodilator action and antiproliferative effect. 5. No production of bradykinin which may be responsible for angioedema and cough seen with ACEIs.
Disadvantages of ARBs 1. Lack of protective effect of bradykinin due to NO & PGs formation. 2. Activation of AT4 receptor responsible for prothrombotic effect with increased fibrinogen, plasminogen activator inhibitor I.
VI. Direct VasodilatorsHydralazine Mechanism of Action It is an arteriolar vasodilator that may act as a K+ channel opener with hyperpolarization of vascular membrane which prevents Ca2+ influx into the wall of blood vessels. Pharmacokinetics It is rapidly absorbed from the gut. It is metabolized in the liver by acetylation. Fast acetylators need large dose, while slow acetylators may develop lupus syndrome. It is excreted by the kidney and the dose should be reduced in renal disease.
Indications :- 1. Hypertension a. IV hydralazine is the drug of choice in severe hypertension with pregnancy. b. The chronic use of hydralazine in hypertension is associated with rapid tolerance due to reflex activation of the sympathetic and renin-angiotensin systems resulting in salt retention and reflex tachycardia. So it is often used with diuretics and b blockers. 2. Congestive Heart Failure It is not used alone but usually combined with nitrates. It potentiates the effect of nitrates by reducing afterload and by reducing nitrate tolerance by decreasing free radical formation.
3. Mitral Regurge Hydralazine, by decreasing peripheral resistance, increases forward stroke volume and decreases regurgitant volume. Adverse Effects Salt retention and edema. Reflex tachycardia. Lupus syndrome.
Sodium Nitroprusside Mechanism of Action It is a donor of nitric oxide (NO) that increases the level of cGMP which induces vasodilation by inhibiting Ca2+ influx into the wall of blood vessels. Pharmacological Properties It has a potent direct vasodilator (arteriolar and venular) effect decreasing both preload and afterload. It has an immediate effect and very short duration of action (2 minutes). It is converted in the body into cyanomethemoglobin and free cyanide which is metabolized into thiocyanate in liver and excreted by the kidney.
Indications :- 1. Hypertensive Emergencies It is useful in most hypertensive emergencies as hypertensive encephalopathy, severe hypertension with acute HF and dissecting aortic aneurysm. 2. Severe Acute Heart Failure It is useful in severe acute HF especially with mitral and aortic regurgitation provided the arterial pressure is reasonable. It may be used in acute HF complicating myocardial infarction, cardiac surgery or acute exacerbation of chronic HF. Nitroprusside is now replaced by safer drugs as nitroglycerin or milrinone (an inotropodilator).
Toxicity 1. Cyanide Toxicity Occurs especially when it is given at high doses for long periods, particularly in liver and renal diseases which limit cyanide clearance. It varies from mild abdominal pain & vomiting to neurological symptoms as headache, confusion and convulsions up to unexplained death. Treatment Sodium nitrate 3% solution 2.5 ml/min for 5 min, followed by sodium thiosulfate 12.5 g in solution of 5% D/W over 10 minutes. Overdose may cause severe hypotension and myocardial ischemia. Dosage: 0.5-10 mg/kg/min IV infusion.
Precautions :- a. Infusion rate needs careful titration against BP, which must be continuously monitored to avoid excessive hypotension (potentially fatal). b. Avoid extravasation. c. Solution in normal saline should be freshly prepared and then protected from light during infusion. d. Solution should be discarded when it is 4 hours old or if it is discolored.
VII. Sympatholytics They include centrally-acting drugs and a1-adrenoceptor blockers. Mechanism of Action of Centrally-Acting Drugs Relmenidine Moxonidine Clonidine Methyldopa Imidazoline Receptor Rostral ventrolateral medulla (RVLM) α2 Receptor Nucleus tractus solitarius (NTS)    Salivary gland (Dryness) Locus ceruleus (Sedation) Central Sympathetic Discharge
Sympatholytics used in Hypertension
Hypertension in the elderly Benefit from antihypetensive therapy is evident up to at least 80 years of age. The thresholds for treatment are diastolic pressure averaging 90 mmHg and systolic pressure averaging 160 mmHg. A low dose of a thiazide is the drug of first choice, with addition of another antihypertensive when necessary.
Isolated Systolic Hypertension ISH (systolic > or = 160, diastolic <90mmHg, should be lowered, even if diastolic hypertension is absent. Treatment with a low dose of a thiazide, with addition of a B-blocker when necessary is effective. A long-acting dihydropyridine CCB is given when a thiazide is contraindicated or not tolerated. Patients with severe postural Hypotension should not receive BP lowering drugs.

Mais conteúdo relacionado

Mais procurados

Pharmacology Cardiovascular Drugs
Pharmacology   Cardiovascular DrugsPharmacology   Cardiovascular Drugs
Pharmacology Cardiovascular Drugspinoy nurze
 
Antiadrenergic system and drugs
Antiadrenergic system and drugsAntiadrenergic system and drugs
Antiadrenergic system and drugsBikashAdhikari26
 
Cardiac glycoside PHARMACOLOGY
Cardiac glycoside PHARMACOLOGYCardiac glycoside PHARMACOLOGY
Cardiac glycoside PHARMACOLOGYBindu Kundu
 
Anti diabetic drugs
Anti diabetic drugsAnti diabetic drugs
Anti diabetic drugsansari425
 
Angina pectoris
Angina pectorisAngina pectoris
Angina pectorisrx_sonali
 
Beta adrenergic blockers
Beta adrenergic blockersBeta adrenergic blockers
Beta adrenergic blockersKarun Kumar
 
Cardiovascular drugs by maghan das
Cardiovascular drugs by maghan dasCardiovascular drugs by maghan das
Cardiovascular drugs by maghan dasMaghan Das
 
Adrenergic system and drugs
Adrenergic system and drugsAdrenergic system and drugs
Adrenergic system and drugsBikashAdhikari26
 
Beta blockers - pharmacology
Beta blockers - pharmacologyBeta blockers - pharmacology
Beta blockers - pharmacologyPARUL UNIVERSITY
 
Drugs used in Congestive heart failure
Drugs used in Congestive heart failure Drugs used in Congestive heart failure
Drugs used in Congestive heart failure shoaib241087
 
Sympathomimetics / ADRENERGICS / SYMPATHOLYTICS
Sympathomimetics / ADRENERGICS / SYMPATHOLYTICSSympathomimetics / ADRENERGICS / SYMPATHOLYTICS
Sympathomimetics / ADRENERGICS / SYMPATHOLYTICSHeena Parveen
 
Renin angiotensin system & drugs
Renin angiotensin system & drugsRenin angiotensin system & drugs
Renin angiotensin system & drugsSurya Prajapat
 
Antihypertension drugs
Antihypertension drugsAntihypertension drugs
Antihypertension drugspriyanka369989
 
Drugs for heart failure
Drugs for heart failureDrugs for heart failure
Drugs for heart failureKarun Kumar
 

Mais procurados (20)

Pharmacology Cardiovascular Drugs
Pharmacology   Cardiovascular DrugsPharmacology   Cardiovascular Drugs
Pharmacology Cardiovascular Drugs
 
Antiadrenergic drugs - drdhriti
Antiadrenergic drugs - drdhritiAntiadrenergic drugs - drdhriti
Antiadrenergic drugs - drdhriti
 
Antiadrenergic system and drugs
Antiadrenergic system and drugsAntiadrenergic system and drugs
Antiadrenergic system and drugs
 
Diuretics
DiureticsDiuretics
Diuretics
 
Cardiac glycoside PHARMACOLOGY
Cardiac glycoside PHARMACOLOGYCardiac glycoside PHARMACOLOGY
Cardiac glycoside PHARMACOLOGY
 
Anti diabetic drugs
Anti diabetic drugsAnti diabetic drugs
Anti diabetic drugs
 
Sympathomimetics
SympathomimeticsSympathomimetics
Sympathomimetics
 
Angina pectoris
Angina pectorisAngina pectoris
Angina pectoris
 
Beta adrenergic blockers
Beta adrenergic blockersBeta adrenergic blockers
Beta adrenergic blockers
 
Cardiovascular drugs by maghan das
Cardiovascular drugs by maghan dasCardiovascular drugs by maghan das
Cardiovascular drugs by maghan das
 
Adrenergic system and drugs
Adrenergic system and drugsAdrenergic system and drugs
Adrenergic system and drugs
 
Beta blockers - pharmacology
Beta blockers - pharmacologyBeta blockers - pharmacology
Beta blockers - pharmacology
 
Drugs used in Congestive heart failure
Drugs used in Congestive heart failure Drugs used in Congestive heart failure
Drugs used in Congestive heart failure
 
Sympathomimetics / ADRENERGICS / SYMPATHOLYTICS
Sympathomimetics / ADRENERGICS / SYMPATHOLYTICSSympathomimetics / ADRENERGICS / SYMPATHOLYTICS
Sympathomimetics / ADRENERGICS / SYMPATHOLYTICS
 
Renin angiotensin system & drugs
Renin angiotensin system & drugsRenin angiotensin system & drugs
Renin angiotensin system & drugs
 
Antihypertension drugs
Antihypertension drugsAntihypertension drugs
Antihypertension drugs
 
Drugs for heart failure
Drugs for heart failureDrugs for heart failure
Drugs for heart failure
 
Vasodilators
VasodilatorsVasodilators
Vasodilators
 
ORAL HYPOGLYCEMIC AGENTS
ORAL HYPOGLYCEMIC AGENTS ORAL HYPOGLYCEMIC AGENTS
ORAL HYPOGLYCEMIC AGENTS
 
ACE inhibitors drugs
ACE inhibitors drugsACE inhibitors drugs
ACE inhibitors drugs
 

Destaque

Cardiac medications
Cardiac medicationsCardiac medications
Cardiac medicationsjjones51
 
Cardiovascular Drugs
Cardiovascular DrugsCardiovascular Drugs
Cardiovascular DrugsJess Little
 
Antibiotic classes
Antibiotic classes Antibiotic classes
Antibiotic classes Khaled Saad
 
Cardiovascular System
Cardiovascular SystemCardiovascular System
Cardiovascular Systemscuffruff
 
Cardiovascular system Pharmacology
Cardiovascular system PharmacologyCardiovascular system Pharmacology
Cardiovascular system Pharmacologymharun5
 
Drugs affecting cardiovascular system
Drugs affecting cardiovascular systemDrugs affecting cardiovascular system
Drugs affecting cardiovascular systemDina Ghoraba
 
Rational Use Of Dopamine And Dobutamine
Rational Use Of  Dopamine And  DobutamineRational Use Of  Dopamine And  Dobutamine
Rational Use Of Dopamine And DobutamineSuman Chowdhury
 
NurseReview.Org Pharmacology Cardiovascular Drugs
NurseReview.Org Pharmacology  Cardiovascular DrugsNurseReview.Org Pharmacology  Cardiovascular Drugs
NurseReview.Org Pharmacology Cardiovascular DrugsNurse ReviewDotOrg
 
Cardiovascular agents - pharmacology
Cardiovascular agents - pharmacologyCardiovascular agents - pharmacology
Cardiovascular agents - pharmacologyCynthia Acosta
 
Common emergency drugs in medicine
Common emergency drugs in medicineCommon emergency drugs in medicine
Common emergency drugs in medicineOluwatobi Olusiyan
 
Pharmacology Review Chapter 1-28
Pharmacology Review Chapter 1-28Pharmacology Review Chapter 1-28
Pharmacology Review Chapter 1-28Carrie Wyatt
 
1 drugs acting on cardiovascular system
1 drugs acting on cardiovascular system1 drugs acting on cardiovascular system
1 drugs acting on cardiovascular systemGyanendra Raj Joshi
 
NurseReview.Org - Study Skills and Test Strategies for the New Nursing Student
NurseReview.Org - Study Skills and Test Strategies for the New Nursing StudentNurseReview.Org - Study Skills and Test Strategies for the New Nursing Student
NurseReview.Org - Study Skills and Test Strategies for the New Nursing StudentNurse ReviewDotOrg
 

Destaque (20)

Cardiovascular drugs
Cardiovascular drugsCardiovascular drugs
Cardiovascular drugs
 
Cardiac medications
Cardiac medicationsCardiac medications
Cardiac medications
 
Cardiovascular Drugs
Cardiovascular DrugsCardiovascular Drugs
Cardiovascular Drugs
 
Antibiotic classes
Antibiotic classes Antibiotic classes
Antibiotic classes
 
IVMS-CV -Cardiovascular Pharmacology Global Review
IVMS-CV -Cardiovascular Pharmacology Global ReviewIVMS-CV -Cardiovascular Pharmacology Global Review
IVMS-CV -Cardiovascular Pharmacology Global Review
 
Cardiovascular System
Cardiovascular SystemCardiovascular System
Cardiovascular System
 
Emergency Drugs
Emergency DrugsEmergency Drugs
Emergency Drugs
 
Cardiovascular system Pharmacology
Cardiovascular system PharmacologyCardiovascular system Pharmacology
Cardiovascular system Pharmacology
 
Heparin
HeparinHeparin
Heparin
 
Cardiac Drugs
Cardiac DrugsCardiac Drugs
Cardiac Drugs
 
Drugs affecting cardiovascular system
Drugs affecting cardiovascular systemDrugs affecting cardiovascular system
Drugs affecting cardiovascular system
 
Rational Use Of Dopamine And Dobutamine
Rational Use Of  Dopamine And  DobutamineRational Use Of  Dopamine And  Dobutamine
Rational Use Of Dopamine And Dobutamine
 
NurseReview.Org Pharmacology Cardiovascular Drugs
NurseReview.Org Pharmacology  Cardiovascular DrugsNurseReview.Org Pharmacology  Cardiovascular Drugs
NurseReview.Org Pharmacology Cardiovascular Drugs
 
Heparin
HeparinHeparin
Heparin
 
Cardiovascular agents - pharmacology
Cardiovascular agents - pharmacologyCardiovascular agents - pharmacology
Cardiovascular agents - pharmacology
 
Common emergency drugs in medicine
Common emergency drugs in medicineCommon emergency drugs in medicine
Common emergency drugs in medicine
 
Pharmacology Review Chapter 1-28
Pharmacology Review Chapter 1-28Pharmacology Review Chapter 1-28
Pharmacology Review Chapter 1-28
 
1 drugs acting on cardiovascular system
1 drugs acting on cardiovascular system1 drugs acting on cardiovascular system
1 drugs acting on cardiovascular system
 
NurseReview.Org - Study Skills and Test Strategies for the New Nursing Student
NurseReview.Org - Study Skills and Test Strategies for the New Nursing StudentNurseReview.Org - Study Skills and Test Strategies for the New Nursing Student
NurseReview.Org - Study Skills and Test Strategies for the New Nursing Student
 
NSAIDS
NSAIDSNSAIDS
NSAIDS
 

Semelhante a Cardiovascular+pharmacology+drug+therapy+of+hypertension

Drugs used in hypertension
Drugs used in hypertensionDrugs used in hypertension
Drugs used in hypertensionGoutam Mallik
 
Drugs used in treatment of Hypertension
Drugs used in treatment of HypertensionDrugs used in treatment of Hypertension
Drugs used in treatment of HypertensionAluru Revathi
 
Antihypertensives and anesthetic implications - Dr. Vaibhav
Antihypertensives and anesthetic implications  - Dr. VaibhavAntihypertensives and anesthetic implications  - Dr. Vaibhav
Antihypertensives and anesthetic implications - Dr. VaibhavVaibhav Tulsyan
 
Pharmacotherapy of heart failure
Pharmacotherapy of heart failurePharmacotherapy of heart failure
Pharmacotherapy of heart failureDr. Shivesh Gupta
 
Essential hypertension management and treatment
Essential hypertension management  and treatmentEssential hypertension management  and treatment
Essential hypertension management and treatmentFabio Grubba
 
The Renin-Angiotensin System is a hormonal system that helps regulate blood p...
The Renin-Angiotensin System is a hormonal system that helps regulate blood p...The Renin-Angiotensin System is a hormonal system that helps regulate blood p...
The Renin-Angiotensin System is a hormonal system that helps regulate blood p...AbhishekRajput1310
 
Antihypertensive agents in Medicinal Chemistry-II
Antihypertensive agents in Medicinal Chemistry-IIAntihypertensive agents in Medicinal Chemistry-II
Antihypertensive agents in Medicinal Chemistry-IIVivek Pete
 
Hypertension pharmacotherapy part 2 ppt
Hypertension pharmacotherapy part 2 pptHypertension pharmacotherapy part 2 ppt
Hypertension pharmacotherapy part 2 pptPranatiChavan
 
lecture-3 hypertantion.pdf
lecture-3 hypertantion.pdflecture-3 hypertantion.pdf
lecture-3 hypertantion.pdfObsa2
 
ANTI HYPERTENSIVE AGENTS [MEDICINAL CHEMISTRY] BY P.RAVISANKAR, HYPERTENSION,...
ANTI HYPERTENSIVE AGENTS [MEDICINAL CHEMISTRY] BY P.RAVISANKAR, HYPERTENSION,...ANTI HYPERTENSIVE AGENTS [MEDICINAL CHEMISTRY] BY P.RAVISANKAR, HYPERTENSION,...
ANTI HYPERTENSIVE AGENTS [MEDICINAL CHEMISTRY] BY P.RAVISANKAR, HYPERTENSION,...Dr. Ravi Sankar
 
Antihypertensive drugs
Antihypertensive drugsAntihypertensive drugs
Antihypertensive drugsKarun Kumar
 

Semelhante a Cardiovascular+pharmacology+drug+therapy+of+hypertension (20)

Drugs used in hypertension
Drugs used in hypertensionDrugs used in hypertension
Drugs used in hypertension
 
Drugs used in treatment of Hypertension
Drugs used in treatment of HypertensionDrugs used in treatment of Hypertension
Drugs used in treatment of Hypertension
 
Hypertension Management
Hypertension ManagementHypertension Management
Hypertension Management
 
Htn05
Htn05Htn05
Htn05
 
Antihypertensives and anesthetic implications - Dr. Vaibhav
Antihypertensives and anesthetic implications  - Dr. VaibhavAntihypertensives and anesthetic implications  - Dr. Vaibhav
Antihypertensives and anesthetic implications - Dr. Vaibhav
 
Pharmacotherapy of heart failure
Pharmacotherapy of heart failurePharmacotherapy of heart failure
Pharmacotherapy of heart failure
 
Essential hypertension management and treatment
Essential hypertension management  and treatmentEssential hypertension management  and treatment
Essential hypertension management and treatment
 
The Renin-Angiotensin System is a hormonal system that helps regulate blood p...
The Renin-Angiotensin System is a hormonal system that helps regulate blood p...The Renin-Angiotensin System is a hormonal system that helps regulate blood p...
The Renin-Angiotensin System is a hormonal system that helps regulate blood p...
 
Antihypertensive agents in Medicinal Chemistry-II
Antihypertensive agents in Medicinal Chemistry-IIAntihypertensive agents in Medicinal Chemistry-II
Antihypertensive agents in Medicinal Chemistry-II
 
Hypertension pharmacotherapy part 2 ppt
Hypertension pharmacotherapy part 2 pptHypertension pharmacotherapy part 2 ppt
Hypertension pharmacotherapy part 2 ppt
 
Antihypertensive drugs 2015-16
Antihypertensive drugs 2015-16Antihypertensive drugs 2015-16
Antihypertensive drugs 2015-16
 
lecture-3 hypertantion.pdf
lecture-3 hypertantion.pdflecture-3 hypertantion.pdf
lecture-3 hypertantion.pdf
 
Antihypertensive drugs
Antihypertensive drugsAntihypertensive drugs
Antihypertensive drugs
 
Lekcia antyhiper
Lekcia antyhiperLekcia antyhiper
Lekcia antyhiper
 
A2
A2A2
A2
 
Hypertension
HypertensionHypertension
Hypertension
 
Antihypertensive drugs
Antihypertensive drugsAntihypertensive drugs
Antihypertensive drugs
 
ANTI HYPERTENSIVE AGENTS [MEDICINAL CHEMISTRY] BY P.RAVISANKAR, HYPERTENSION,...
ANTI HYPERTENSIVE AGENTS [MEDICINAL CHEMISTRY] BY P.RAVISANKAR, HYPERTENSION,...ANTI HYPERTENSIVE AGENTS [MEDICINAL CHEMISTRY] BY P.RAVISANKAR, HYPERTENSION,...
ANTI HYPERTENSIVE AGENTS [MEDICINAL CHEMISTRY] BY P.RAVISANKAR, HYPERTENSION,...
 
Antihypertensive drugs
Antihypertensive drugsAntihypertensive drugs
Antihypertensive drugs
 
Hypertension drug therapy
Hypertension   drug therapyHypertension   drug therapy
Hypertension drug therapy
 

Mais de Dr.Ebrahim Eltanbouly

Pharmacology .. Treatment of Epilepsy
Pharmacology .. Treatment of EpilepsyPharmacology .. Treatment of Epilepsy
Pharmacology .. Treatment of EpilepsyDr.Ebrahim Eltanbouly
 
Pharmacology .. Anti-Depressants Drugs
Pharmacology .. Anti-Depressants DrugsPharmacology .. Anti-Depressants Drugs
Pharmacology .. Anti-Depressants DrugsDr.Ebrahim Eltanbouly
 
Pharmacology .. Opioid Analgesics (Nacrotic analgesic)
Pharmacology .. Opioid Analgesics (Nacrotic analgesic)Pharmacology .. Opioid Analgesics (Nacrotic analgesic)
Pharmacology .. Opioid Analgesics (Nacrotic analgesic)Dr.Ebrahim Eltanbouly
 
Pharmacology .. Sedative & Hypnotic Drugs
Pharmacology .. Sedative & Hypnotic DrugsPharmacology .. Sedative & Hypnotic Drugs
Pharmacology .. Sedative & Hypnotic DrugsDr.Ebrahim Eltanbouly
 
Pharmacology.. Treatment of Peptic Ulcer
Pharmacology.. Treatment of Peptic UlcerPharmacology.. Treatment of Peptic Ulcer
Pharmacology.. Treatment of Peptic UlcerDr.Ebrahim Eltanbouly
 
P H R M A C O L O G Y.. Treatment of Cough
P H R M A C O L O G Y.. Treatment of CoughP H R M A C O L O G Y.. Treatment of Cough
P H R M A C O L O G Y.. Treatment of CoughDr.Ebrahim Eltanbouly
 
تأخير وجبة السحور.. أسرار علمية
تأخير وجبة السحور.. أسرار علمية تأخير وجبة السحور.. أسرار علمية
تأخير وجبة السحور.. أسرار علمية Dr.Ebrahim Eltanbouly
 
Human Anatomy&Physiology Respiratory S.
Human Anatomy&Physiology Respiratory S.Human Anatomy&Physiology Respiratory S.
Human Anatomy&Physiology Respiratory S.Dr.Ebrahim Eltanbouly
 
أشهر اللقاحات المهمة للبالغين
أشهر اللقاحات المهمة للبالغين أشهر اللقاحات المهمة للبالغين
أشهر اللقاحات المهمة للبالغين Dr.Ebrahim Eltanbouly
 
الجنسنج..نبات يجد مكانه في الطب البديل
الجنسنج..نبات يجد مكانه في الطب البديل الجنسنج..نبات يجد مكانه في الطب البديل
الجنسنج..نبات يجد مكانه في الطب البديل Dr.Ebrahim Eltanbouly
 
اختلال هرمونات الغده الدرقيه ...الاعراض والعلاج(للمرأة)
اختلال هرمونات الغده الدرقيه ...الاعراض والعلاج(للمرأة)اختلال هرمونات الغده الدرقيه ...الاعراض والعلاج(للمرأة)
اختلال هرمونات الغده الدرقيه ...الاعراض والعلاج(للمرأة)Dr.Ebrahim Eltanbouly
 
قبلة الحياة .. قد تنقذ حياتك
قبلة الحياة .. قد تنقذ حياتكقبلة الحياة .. قد تنقذ حياتك
قبلة الحياة .. قد تنقذ حياتكDr.Ebrahim Eltanbouly
 
ماذا تعرف عن فوائد حبة البركة .
ماذا تعرف عن فوائد حبة البركة .ماذا تعرف عن فوائد حبة البركة .
ماذا تعرف عن فوائد حبة البركة .Dr.Ebrahim Eltanbouly
 

Mais de Dr.Ebrahim Eltanbouly (20)

Pharmacology .. Treatment of Epilepsy
Pharmacology .. Treatment of EpilepsyPharmacology .. Treatment of Epilepsy
Pharmacology .. Treatment of Epilepsy
 
Pharmacology .. Anit-migraine Drugs
Pharmacology .. Anit-migraine DrugsPharmacology .. Anit-migraine Drugs
Pharmacology .. Anit-migraine Drugs
 
Pharmacology .. Anti-Depressants Drugs
Pharmacology .. Anti-Depressants DrugsPharmacology .. Anti-Depressants Drugs
Pharmacology .. Anti-Depressants Drugs
 
Pharmacology .. Opioid Analgesics (Nacrotic analgesic)
Pharmacology .. Opioid Analgesics (Nacrotic analgesic)Pharmacology .. Opioid Analgesics (Nacrotic analgesic)
Pharmacology .. Opioid Analgesics (Nacrotic analgesic)
 
Pharmacology .. Sedative & Hypnotic Drugs
Pharmacology .. Sedative & Hypnotic DrugsPharmacology .. Sedative & Hypnotic Drugs
Pharmacology .. Sedative & Hypnotic Drugs
 
Pharmacology.. Treatment of Peptic Ulcer
Pharmacology.. Treatment of Peptic UlcerPharmacology.. Treatment of Peptic Ulcer
Pharmacology.. Treatment of Peptic Ulcer
 
P H R M A C O L O G Y.. Treatment of Cough
P H R M A C O L O G Y.. Treatment of CoughP H R M A C O L O G Y.. Treatment of Cough
P H R M A C O L O G Y.. Treatment of Cough
 
Pharmacology ..Treatment of Asthma
Pharmacology ..Treatment of AsthmaPharmacology ..Treatment of Asthma
Pharmacology ..Treatment of Asthma
 
تأخير وجبة السحور.. أسرار علمية
تأخير وجبة السحور.. أسرار علمية تأخير وجبة السحور.. أسرار علمية
تأخير وجبة السحور.. أسرار علمية
 
دليلك لعلاج الحروق
دليلك لعلاج الحروق دليلك لعلاج الحروق
دليلك لعلاج الحروق
 
Human Anatomy&Physiology Respiratory S.
Human Anatomy&Physiology Respiratory S.Human Anatomy&Physiology Respiratory S.
Human Anatomy&Physiology Respiratory S.
 
أشهر اللقاحات المهمة للبالغين
أشهر اللقاحات المهمة للبالغين أشهر اللقاحات المهمة للبالغين
أشهر اللقاحات المهمة للبالغين
 
الجنسنج..نبات يجد مكانه في الطب البديل
الجنسنج..نبات يجد مكانه في الطب البديل الجنسنج..نبات يجد مكانه في الطب البديل
الجنسنج..نبات يجد مكانه في الطب البديل
 
اختلال هرمونات الغده الدرقيه ...الاعراض والعلاج(للمرأة)
اختلال هرمونات الغده الدرقيه ...الاعراض والعلاج(للمرأة)اختلال هرمونات الغده الدرقيه ...الاعراض والعلاج(للمرأة)
اختلال هرمونات الغده الدرقيه ...الاعراض والعلاج(للمرأة)
 
قبلة الحياة .. قد تنقذ حياتك
قبلة الحياة .. قد تنقذ حياتكقبلة الحياة .. قد تنقذ حياتك
قبلة الحياة .. قد تنقذ حياتك
 
ماذا تعرف عن فوائد حبة البركة .
ماذا تعرف عن فوائد حبة البركة .ماذا تعرف عن فوائد حبة البركة .
ماذا تعرف عن فوائد حبة البركة .
 
تساقط الشعر
تساقط الشعرتساقط الشعر
تساقط الشعر
 
Pharmacy magazine ..3
Pharmacy magazine ..3Pharmacy magazine ..3
Pharmacy magazine ..3
 
Pharmacy magazine .. 2
Pharmacy magazine .. 2Pharmacy magazine .. 2
Pharmacy magazine .. 2
 
Pharmacy magazine .. 1
Pharmacy magazine .. 1Pharmacy magazine .. 1
Pharmacy magazine .. 1
 

Último

The basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptxThe basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptxheathfieldcps1
 
Beyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global ImpactBeyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global ImpactPECB
 
Z Score,T Score, Percential Rank and Box Plot Graph
Z Score,T Score, Percential Rank and Box Plot GraphZ Score,T Score, Percential Rank and Box Plot Graph
Z Score,T Score, Percential Rank and Box Plot GraphThiyagu K
 
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptxSOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptxiammrhaywood
 
Arihant handbook biology for class 11 .pdf
Arihant handbook biology for class 11 .pdfArihant handbook biology for class 11 .pdf
Arihant handbook biology for class 11 .pdfchloefrazer622
 
Kisan Call Centre - To harness potential of ICT in Agriculture by answer farm...
Kisan Call Centre - To harness potential of ICT in Agriculture by answer farm...Kisan Call Centre - To harness potential of ICT in Agriculture by answer farm...
Kisan Call Centre - To harness potential of ICT in Agriculture by answer farm...Krashi Coaching
 
1029 - Danh muc Sach Giao Khoa 10 . pdf
1029 -  Danh muc Sach Giao Khoa 10 . pdf1029 -  Danh muc Sach Giao Khoa 10 . pdf
1029 - Danh muc Sach Giao Khoa 10 . pdfQucHHunhnh
 
Student login on Anyboli platform.helpin
Student login on Anyboli platform.helpinStudent login on Anyboli platform.helpin
Student login on Anyboli platform.helpinRaunakKeshri1
 
Interactive Powerpoint_How to Master effective communication
Interactive Powerpoint_How to Master effective communicationInteractive Powerpoint_How to Master effective communication
Interactive Powerpoint_How to Master effective communicationnomboosow
 
Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104misteraugie
 
Call Girls in Dwarka Mor Delhi Contact Us 9654467111
Call Girls in Dwarka Mor Delhi Contact Us 9654467111Call Girls in Dwarka Mor Delhi Contact Us 9654467111
Call Girls in Dwarka Mor Delhi Contact Us 9654467111Sapana Sha
 
Holdier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfHoldier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfagholdier
 
Measures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and ModeMeasures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and ModeThiyagu K
 
IGNOU MSCCFT and PGDCFT Exam Question Pattern: MCFT003 Counselling and Family...
IGNOU MSCCFT and PGDCFT Exam Question Pattern: MCFT003 Counselling and Family...IGNOU MSCCFT and PGDCFT Exam Question Pattern: MCFT003 Counselling and Family...
IGNOU MSCCFT and PGDCFT Exam Question Pattern: MCFT003 Counselling and Family...PsychoTech Services
 
Key note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfKey note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfAdmir Softic
 
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...christianmathematics
 
Activity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdfActivity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdfciinovamais
 
APM Welcome, APM North West Network Conference, Synergies Across Sectors
APM Welcome, APM North West Network Conference, Synergies Across SectorsAPM Welcome, APM North West Network Conference, Synergies Across Sectors
APM Welcome, APM North West Network Conference, Synergies Across SectorsAssociation for Project Management
 

Último (20)

The basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptxThe basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptx
 
Beyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global ImpactBeyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global Impact
 
Z Score,T Score, Percential Rank and Box Plot Graph
Z Score,T Score, Percential Rank and Box Plot GraphZ Score,T Score, Percential Rank and Box Plot Graph
Z Score,T Score, Percential Rank and Box Plot Graph
 
Advance Mobile Application Development class 07
Advance Mobile Application Development class 07Advance Mobile Application Development class 07
Advance Mobile Application Development class 07
 
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptxSOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
 
Arihant handbook biology for class 11 .pdf
Arihant handbook biology for class 11 .pdfArihant handbook biology for class 11 .pdf
Arihant handbook biology for class 11 .pdf
 
Kisan Call Centre - To harness potential of ICT in Agriculture by answer farm...
Kisan Call Centre - To harness potential of ICT in Agriculture by answer farm...Kisan Call Centre - To harness potential of ICT in Agriculture by answer farm...
Kisan Call Centre - To harness potential of ICT in Agriculture by answer farm...
 
1029 - Danh muc Sach Giao Khoa 10 . pdf
1029 -  Danh muc Sach Giao Khoa 10 . pdf1029 -  Danh muc Sach Giao Khoa 10 . pdf
1029 - Danh muc Sach Giao Khoa 10 . pdf
 
Student login on Anyboli platform.helpin
Student login on Anyboli platform.helpinStudent login on Anyboli platform.helpin
Student login on Anyboli platform.helpin
 
Interactive Powerpoint_How to Master effective communication
Interactive Powerpoint_How to Master effective communicationInteractive Powerpoint_How to Master effective communication
Interactive Powerpoint_How to Master effective communication
 
Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104
 
Call Girls in Dwarka Mor Delhi Contact Us 9654467111
Call Girls in Dwarka Mor Delhi Contact Us 9654467111Call Girls in Dwarka Mor Delhi Contact Us 9654467111
Call Girls in Dwarka Mor Delhi Contact Us 9654467111
 
Holdier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfHoldier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdf
 
Measures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and ModeMeasures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and Mode
 
IGNOU MSCCFT and PGDCFT Exam Question Pattern: MCFT003 Counselling and Family...
IGNOU MSCCFT and PGDCFT Exam Question Pattern: MCFT003 Counselling and Family...IGNOU MSCCFT and PGDCFT Exam Question Pattern: MCFT003 Counselling and Family...
IGNOU MSCCFT and PGDCFT Exam Question Pattern: MCFT003 Counselling and Family...
 
Key note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfKey note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdf
 
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
 
INDIA QUIZ 2024 RLAC DELHI UNIVERSITY.pptx
INDIA QUIZ 2024 RLAC DELHI UNIVERSITY.pptxINDIA QUIZ 2024 RLAC DELHI UNIVERSITY.pptx
INDIA QUIZ 2024 RLAC DELHI UNIVERSITY.pptx
 
Activity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdfActivity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdf
 
APM Welcome, APM North West Network Conference, Synergies Across Sectors
APM Welcome, APM North West Network Conference, Synergies Across SectorsAPM Welcome, APM North West Network Conference, Synergies Across Sectors
APM Welcome, APM North West Network Conference, Synergies Across Sectors
 

Cardiovascular+pharmacology+drug+therapy+of+hypertension

  • 2. Cardiovascular PharmacologyManagement of Hypertension Dr. Mohamed saad
  • 3. Cardiovascular PharmacologyManagement of hypertension Hypertension is a major health problem with prevalence rate of 25% among adults, increasing to 50% among those above 60 years. Hypertension causes dangerous complications (Target Organ Damage [TOD]) such as myocardial infarction, heart failure, aortic aneurysm, stroke and renal failure. These complications occur commonly in high risk patients as males, elderly, smokers, diabetics, and those with high cholesterol levels.
  • 4.
  • 5.
  • 6. Target Blood Pressure <140/90 in low-risk group <130/85 in high-risk group
  • 7. Lifestyle Modification (Nonpharmacological Management of Hypertension) Beneficial in reducing high blood pressure and its complications. Reduces the dose requirement of antihypertensive drugs. Recommended in all hypertensives initially and with drug therapy.
  • 8. Lifestyle modification includes :- (1). Reduced dietary intake of Na+ and fat, increased Ca2+ and K+ intake, together with diet rich in fruits and vegetables and low-fat dairy products. (2). Weight reduction for overweight patients. (3). Regular physical exercise. (4). Stopping smoking and reducing alcohol intake
  • 9. 3. Sympatholytics 2. b Blockers NE early late Vasospasm Angiotensin II Vasodilators 4. Angiotensin Converting Enzyme Inhibitors (ACEIs) 1. Diuretics 5. Angiotensin Receptor Blockers (ARBs) 6. Calcium Channel Blockers 7. Direct Vasodilators Classification of Antihypertensive Drugs Centrally-acting  a1-blockers    BP COP TPR = ×  
  • 10. NB: Hypertensive patients can be classified into salt-sensitive and salt-resistant patients. Salt-sensitive hypertension is more common in elderly, obese, black, and patients with renal disease. These patients have impaired renal Na+ excretion leading to Na+ retention with increased Na+-Ca2+ exchange and vasoconstriction and low renin status. Hypertension in these patients gives better response to diuretics and calcium channel blockers with poor response to B-blockers and ACEIs which act mainly in high-renin status.
  • 11. I. Diuretics Mechanism of Action Initially, they act by reducing plasma volume and COP, followed by vasodilation and reduction in peripheral vascular resistance. Advantages Reduce mortality, stroke and cardiovascular complications of hypertension. The least expensive antihypertensives.
  • 12. Indications 1st choice in uncomplicated hypertension. Specially indicated in: 1. Systolic hypertension. 2. Hypertension in elderly, black and obese patients (salt-sensitive). 3. Hypertension complicated with heart failure. Combined with other antihypertensives to potentiate their effect: 1. Control edema of vasodilators. 2. Reduce plasma volume -> increase renin and potentiate the hypotensive action of ACEIs and b blockers, especially in black old patients.
  • 13. Thiazides are the preferred diuretics for hypertension because in single daily dose they cause persistent volume depletion which is required to lower BP; whereas once daily dose of frusemide is inadequate as it causes temporary Na+ loss. Thiazides tend to retain Ca2+ -> ↓ risk of bone fracture in the elderly.
  • 14. Preparations and Dosage Hydrochlorothiazide: low (12.5 mg) or lower (6.25 mg) dose combined with an ACEI or a b blocker has adequate antihypertensive effect with fewer side effects. Indapamide: a thiazide-like agent with more vasodilator effect and less side effects especially in low-dose (1.25 mg) slow-release preparations. Frusemide: orally 2-3 times daily in hypertension with renal impairment in which case thiazide diuretics are not effective due to decreased GFR.
  • 15. Side Effects-: 1. Metabolic Side Effects Hyperuricemia - hyperglycemia -hyperlipidemia. 2. Electrolyte Disturbances Hypokalemia - hyponatremia -hypomagnesemia.
  • 16. These side effects can be minimized by:- a. Low-sodium and high-potassium diet. b. Using low dose of thiazide especially when combined with b blockers to avoid unfavorable additive metabolic effects. c. Combination with spironolactone in cardiac patients to avoid the dangerous effects of hypokalemia and hypomagnesemia. d. Combination with ACEIs which may neutralize these effects.
  • 17. 3. Impotence (common). 4. Sulfonamide hypersensitivity reactions (rare) as jaundice, pancreatitis and blood disorders.
  • 18. II. B-Adrenergic Blockers Mechanism of Action-: Initially, they decrease COP without effective drop in BP due to reflex vasospasm with early increase in TPR. Later, they decrease TPR and BP through: a. ↓ Renin release. b. ↓ NE release by central and peripheral effects. c. ↑ PG causing VD.
  • 19. Advantages Decrease cardiovascular mortality & morbidity and protect against coronary heart disease. Relatively not expensive. Indications Alternative to diuretics as 1st line treatment of uncomplicated hypertension. Used in young hypertensives where COP is high. Hypertension associated with coronary heart disease.
  • 20. Preparations and Dosage The ideal antihypertensive B-blocker would be long-acting (once-daily) and b1-selective. It is best to start with low dose to lessen the initial side effects as fatigue and bradycardia due to ↓ COP. If the ordinary dose is inadequate, it is better to combine with another drug rather than to increase the dose. Atenolol 25-100 mg Bisoprolol 2.5-10 mg. Metoprolol 50-200 mg.
  • 21. B-Blocker Combinations in Hypertension 1. b Blockers plus Diuretics Diuretics acting by Na+ loss increase renin secretion -> VC by angiotensin II thus offsetting their hypotensive effect. b Blockers inhibit renin release -> potentiate the hypotensive effect of diuretics. On the other hand, diuretics, by increasing renin level, potentiate the hypotensive effect of b blockers in low-renin hypertensives as black elderly patients. For initial therapy of hypertension, the lowest effective dose of both drugs [bisoprolol (2.5 mg) and hydrochlorothiazide (6.25 mg)] is recommended to avoid possible additive metabolic side effects such as hyperglycemia and hyperlipidemia.
  • 22. 2. B-Blockers plus Dihydropyridine (DHP) Ca2+ Channel Blockers DHP Ca2+ channel blockers induce vasodilator effect and reflex tachycardia, offsetting a possible vasospasm and bradycardia induced by b blockers.
  • 23. Side Effects (Less with B1-selective): 1. Bronchospasm, cold extremities. 2. Metabolic: glucose intolerance, dyslipidemia. 3. Bradycardia, heart block. 4. CNS depression, sense of fatigue. 5. Impotence.
  • 24. III. Calcium Channel Blockers There are two main types of voltage-dependent Ca2+ channels:- 1. L-type (Long-lasting) with slow inactivation and high conductivity. 2. T-type (Transient) with fast inactivation and low conductivity. Ca2+ channel blockers act on α1 subunit of L-type channel that is located in conductive tissues (SAN & AVN) cardiac myocytes and vascular smooth muscle including coronaries.
  • 25. Classification, Actions, Uses and Adverse Reactions of Calcium Channel Blockers
  • 26. Calcium Channel Blockers for Hypertension Mechanism of Action Peripheral VD and ↓ TPR. Diuretic action secondary to ↑ renal blood flow. ↓ Aldosterone secretion. Advantages No metabolic side effects (no changes in glucose, lipid or uric acid levels). No affection of sexual activity. May improve renal function.
  • 27. Indications : 2nd Choice after diuretics in elderly hypertensives or in isolated systolic hypertension. 2nd Choice after b blockers in hypertensives with coronary heart disease. Hypertension with peripheral vascular disease (PVD). Hypertension with renal impairment. Preparations and Dosage: Amlodipine 5 mg once daily. Verapamil 240 mg SR once daily.
  • 28.
  • 29.
  • 30.  Sympathetic (central + peripheral).
  • 31. ↑ Aldosterone (Na+ retention).
  • 32. ↑ ADH (water retention).
  • 33.
  • 34. Mechanism of Action of ACEIs: ACEIs have dual vasodilator action by: 1. ↓ Angiotensin II formation which mediates most of its effects through activation of AT1 receptors (inhibits vasospasm, salt & water retention & cardiac & vascular remodeling induced by angiotensin II). ↓ Activity of angiotensin II at AT2 receptors -> minimizes vasodilator effect of ACEIs (a disadvantage compared to ARBs). ↓ Activity of angiotensin II at AT4 receptors -> ↓its prothrombotic effect mediated by ↑ fibrinogen & PAI1 (an advantage over ARBs). 2. ↑ Bradykinin through inhibition of its deactivation -> direct VD & release of potent vasodilator PGs and NO from vascular endothelium.
  • 35. Therapeutic Uses of ACEIs I. Cardiovascular Uses ACE inhibitors have unique effects in preventing and treating cardiovascular diseases. They act on sequential events from risk factors to left ventricular failure.
  • 36. The main cardiovascular indications of ACEIs are: Major risk factors 1. Hypertension: ↓ BP, } Major risk factors ↓ LV hypertrophy 2. Ischemic heart disease: inhibits atherogenesis and thrombogenesis. 3. Myocardial infarction: Early administration during acute attacks prevents sudden death by preventing arrhythmia induced by hypokalemia and sympathetic overactivity. Decrease postinfarction remodeling caused by aldosterone and prevent heart failure. 4. Heart failure: used in all stages of heart failure. Major risk factors
  • 37. II. Nephropathy (diabetic or nondiabetic) ACEIs decrease intraglomerular pressure, progressive glomerulosclerosis, and proteinuria and delay the onset of renal failure.
  • 38.
  • 39.
  • 42.
  • 43. Class I Captopril (SH) Class II Enalapril - Perindopril Ramipril - Fosinopril Class III Lisinopril Classification of ACEIs
  • 44. Class I (Captopril) : Not a prodrug. Rapid onset & short duration (t½ 4-6 h), can be given sublingually in severe hypertension ↓ Nitrate tolerance (due to its SH group). Class II (Enalapril - Perindopril - Ramipril - Fosinopril): Prodrugs (activated first in liver). Slow onset & long duration (given once/day). Have carboxyl group not SH group with absence of immune base side effects of captopril. Fosinopril has phosphoryl group instead of carboxyl group with dual route of excretion (hepatic & renal) -> no dose adjustment in renal failure.
  • 45. Classification (contin) Class III (lisinopril) : Not a prodrug. Long duration. Water soluble, not metabolized in liver and excreted unchanged by the kidney -> given in liver disease.
  • 46. ACE Inhibitors in Hypertension Mechanism of Action 1. Vasodilation due to ↓ angiotensin II & ↑ vasodilator BK, PGs & NO. 2. Anti-adrenergic effect by blocking central & peripheral adrenergic activity of angiotensin II (thus ACEIs decrease BP without reflex tachycardia). 3. Inhibition of aldosterone -> Na+ loss.
  • 47. Advantages 1. ↓ Cardiovascular mortality and morbidity. 2. Protect renal function especially in diabetics. 3. No metabolic side effects (no effect on glucose, lipid or uric acid). 4. May improve glucose intolerance in insulin resistance. 5. No changes in heart rate. Indications 1. Diabetic hypertensives. 2. Hypertension with nephropathy in diabetics or nondiabetics. 3. Hypertension in HF or after myocardial infarction.
  • 48. V. Angiotensin II Receptor Blockers (ARBs)(Losartan - Valsartan - Telmisartan) They block angiotensin II receptor type I (AT1) responsible for most of the damaging effects of angiotensin II (see figure p. 179). Advantages of ARBs over ACEIs 1. Antagonize AG II formed by both ACE & non-ACE pathway (e.g. chymase). 2. They are able to avoid hormonal "escape" (↑ renin & angiotensin II) which may occur during prolonged administration of ACEIs. 3. They block the hypersensitivity of AT1 receptor caused by insulin or LDL. 4. Blocking AT1 receptor directs angiotensin II to AT2 receptor which has vasodilator action and antiproliferative effect. 5. No production of bradykinin which may be responsible for angioedema and cough seen with ACEIs.
  • 49. Disadvantages of ARBs 1. Lack of protective effect of bradykinin due to NO & PGs formation. 2. Activation of AT4 receptor responsible for prothrombotic effect with increased fibrinogen, plasminogen activator inhibitor I.
  • 50. VI. Direct VasodilatorsHydralazine Mechanism of Action It is an arteriolar vasodilator that may act as a K+ channel opener with hyperpolarization of vascular membrane which prevents Ca2+ influx into the wall of blood vessels. Pharmacokinetics It is rapidly absorbed from the gut. It is metabolized in the liver by acetylation. Fast acetylators need large dose, while slow acetylators may develop lupus syndrome. It is excreted by the kidney and the dose should be reduced in renal disease.
  • 51. Indications :- 1. Hypertension a. IV hydralazine is the drug of choice in severe hypertension with pregnancy. b. The chronic use of hydralazine in hypertension is associated with rapid tolerance due to reflex activation of the sympathetic and renin-angiotensin systems resulting in salt retention and reflex tachycardia. So it is often used with diuretics and b blockers. 2. Congestive Heart Failure It is not used alone but usually combined with nitrates. It potentiates the effect of nitrates by reducing afterload and by reducing nitrate tolerance by decreasing free radical formation.
  • 52. 3. Mitral Regurge Hydralazine, by decreasing peripheral resistance, increases forward stroke volume and decreases regurgitant volume. Adverse Effects Salt retention and edema. Reflex tachycardia. Lupus syndrome.
  • 53. Sodium Nitroprusside Mechanism of Action It is a donor of nitric oxide (NO) that increases the level of cGMP which induces vasodilation by inhibiting Ca2+ influx into the wall of blood vessels. Pharmacological Properties It has a potent direct vasodilator (arteriolar and venular) effect decreasing both preload and afterload. It has an immediate effect and very short duration of action (2 minutes). It is converted in the body into cyanomethemoglobin and free cyanide which is metabolized into thiocyanate in liver and excreted by the kidney.
  • 54. Indications :- 1. Hypertensive Emergencies It is useful in most hypertensive emergencies as hypertensive encephalopathy, severe hypertension with acute HF and dissecting aortic aneurysm. 2. Severe Acute Heart Failure It is useful in severe acute HF especially with mitral and aortic regurgitation provided the arterial pressure is reasonable. It may be used in acute HF complicating myocardial infarction, cardiac surgery or acute exacerbation of chronic HF. Nitroprusside is now replaced by safer drugs as nitroglycerin or milrinone (an inotropodilator).
  • 55. Toxicity 1. Cyanide Toxicity Occurs especially when it is given at high doses for long periods, particularly in liver and renal diseases which limit cyanide clearance. It varies from mild abdominal pain & vomiting to neurological symptoms as headache, confusion and convulsions up to unexplained death. Treatment Sodium nitrate 3% solution 2.5 ml/min for 5 min, followed by sodium thiosulfate 12.5 g in solution of 5% D/W over 10 minutes. Overdose may cause severe hypotension and myocardial ischemia. Dosage: 0.5-10 mg/kg/min IV infusion.
  • 56. Precautions :- a. Infusion rate needs careful titration against BP, which must be continuously monitored to avoid excessive hypotension (potentially fatal). b. Avoid extravasation. c. Solution in normal saline should be freshly prepared and then protected from light during infusion. d. Solution should be discarded when it is 4 hours old or if it is discolored.
  • 57. VII. Sympatholytics They include centrally-acting drugs and a1-adrenoceptor blockers. Mechanism of Action of Centrally-Acting Drugs Relmenidine Moxonidine Clonidine Methyldopa Imidazoline Receptor Rostral ventrolateral medulla (RVLM) α2 Receptor Nucleus tractus solitarius (NTS)    Salivary gland (Dryness) Locus ceruleus (Sedation) Central Sympathetic Discharge
  • 58. Sympatholytics used in Hypertension
  • 59. Hypertension in the elderly Benefit from antihypetensive therapy is evident up to at least 80 years of age. The thresholds for treatment are diastolic pressure averaging 90 mmHg and systolic pressure averaging 160 mmHg. A low dose of a thiazide is the drug of first choice, with addition of another antihypertensive when necessary.
  • 60. Isolated Systolic Hypertension ISH (systolic > or = 160, diastolic <90mmHg, should be lowered, even if diastolic hypertension is absent. Treatment with a low dose of a thiazide, with addition of a B-blocker when necessary is effective. A long-acting dihydropyridine CCB is given when a thiazide is contraindicated or not tolerated. Patients with severe postural Hypotension should not receive BP lowering drugs.
  • 61. Hypertension in Diabetes The aim should be to maintain SBP<130 and DBP<80 mmHg. HTN is common in type 2 DM and treatment of HTN prevents macrovascular and microvascular complications. In type I DM, HTN usually indicates diabetic nephropathy. An ACEI or ARB may have a specific role in the management of diabetic nephropathy. In type 2, an ACEI or ARB can delay progression of microalbuminuria to nephropathy.
  • 62. Hypertension in renal disease The thresholds for treatment in are diastolic pressure averaging 90 mmHg and systolic pressure averaging 140 mmHg. Optimal BP is a SBP <130 and a DBP<80 mmHg if proteinuria exeeds 1 g in 24 h. Thiazides may be ineffective and high doses of loop diuretics may be required. Specific cautions apply to the use of ACEI in renal impairment, but ACEIs may be effective. DHP CCBs may be added.
  • 63. Hypertension in Pregnancy High BP in pregnancy may usually be due to pre-existing essential HTN or to pre-eclampsia. Methyldopa is safe in pregnancy. B-blockers are effective and safe in the third trimester. Modified release preparations of nifedipine are also used in HTN in pregnancy. IV labetalol or hydralazine can be used to control hypertensive crisis. Magnesium sulphate is the drug of choice to prevent seizures in pre-eclampsia and eclampsia
  • 64. Hypertensive Crisis Hypertensive crisis is defined as severe elevation in BP usually a systolic BP exceeding 220 mmHg and/or a diastolic BP greater than 120 mmHg. It includes hypertensive emergencies and hypertensive urgencies. Hypertensive Urgencies It is severe elevation of BP in absence of progressive target-organ damage. Immediate reduction in BP is not indicated and can be managed as outpatient case using combination of oral antihypertensives. Hypertensive Emergencies It is severe elevation in BP with acute progressive target-organ damage. It represents an acute life-threatening situation which requires ICU admission for immediate controlled reduction in BP using IV drug therapy to avoid death or irreversible organ damage.
  • 65. Clinical Conditions Associated with HypertensiveEmergencies & their Drug Therapy :- 1. Malignant Hypertension It is associated with bilateral retinal hemorrhage and/or exudates with or without papilledema. Fenoldopam D1 agonist is the preferred drug, as it ↑ renal blood flow. Other drugs: labetalol, enalaprilat. 2. Hypertensive Encephalopathy It is associated with neurological manifestations as headache, vomiting, visual disturbance, confusion or convulsions. BP should be reduced gradually not to normal level to avoid brain ischemia. Preferred drugs: labetalol, nitroprusside. Nimodipine is used in subarachnoid hemorrhage -> ↓ cerebral vasospasm.
  • 66. 3. Acute Coronary Syndrome (unstable angina & myocardial infarction) Nitroglycerin, esmolol are preferred drugs. Nitroprusside is preserved for resistant cases as it may ↓ coronary BF. 4. Acute Left Ventricular Failure Enalaprilat, nitroglycerin and nitroprusside are preferred. b Blockers are avoided. 5. Dissecting Aortic Aneurysm Drugs used: esmolol and nitroprusside.
  • 67. 6. Excessive Circulating Catecholamines Occurs in pheochromocytoma, clonidine withdrawal and food interaction with MAO inhibitors. Drugs used: phentolamine (plus b blockers) or labetalol (without b Bs) 7. Eclampsia Hydralazine, nitroglycerin, labetalol may be used. 8. Perioperative Includes severe hypertension in patient requiring immediate surgery or postoperative hypertension (↑ risk of myocardial infarction). Drugs used: nitroglycerin, esmolol, labetalol, nitroprusside.
  • 68. Parenteral Agents for Hypertensive Emergencies